Considering that IGF1R deregulation is not limited to ErbB2+ breast cancer, our data widen the scope of breast cancer subtypes that may respond to phenformin treatment to include ErbB2-negative breast cancer with IGF1R deregulation, yet further investigation is necessary. Here, ERBB2 is linked to breast cancer.